<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, July 9, 2018 (HealthDay News) — The addition of budesonide to a saline nasal lavage for the treatment of chronic rhinosinusitis provides clinically meaningful benefits, according to a study published online June 7 in JAMA Otolaryngology-Head & Neck Surgery<\/i>.<\/p>\n
Sarah Tait, from the Washington University School of Medicine in St. Louis, and colleagues performed a double-blind, placebo-controlled randomized trial to evaluate the incremental effect of adding budesonide to large-volume, low-pressure saline sinus irrigation for the treatment of chronic rhinosinusitis. A total of 80 patients were enrolled, and 61 completed all analyses. Participants were provided with a sinus rinse kit that included saline and capsules containing either budesonide (treatment group) or lactose (control group).<\/p>\n
The researchers found that the budesonide group had a mean score on the Sino-Nasal Outcome Test (SNOT-22) that was 7 points better (95 percent confidence interval, \u22122 to 16) than the control group, with 79 percent in the budesonide group experiencing a clinically meaningful reduction in their SNOT-22 scores versus 59 percent in the control group, for a difference of 20 percent (95 percent confidence interval, \u22122.5 to 42.5 percent). The average change in endoscopic scores also favored the budesonide group.<\/p>\n
“Given the imprecision in the treatment effect, further research is warranted to define the true effect of budesonide in saline nasal lavage,” the authors write.<\/p>\n
One author received royalty income for use of the SNOT-22 instrument. NeilMed provided the rinse bottles and saline solution for the study.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n